{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T10:07:17.228643+00:00","company":{"ticker":"BSX","cik":885725,"company_name":"BOSTON SCIENTIFIC CORP"},"pagination":{"limit":100,"returned":16,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"70cc581e8f2faf9858999344c49c7a060148f911","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-05-05T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-05-05","item_codes_triggered":["5.03"],"summary_text":"Stockholders approved amendments to the Third Restated Certificate of Incorporation to eliminate supermajority voting provisions, implement clarifying changes, and provide for officer exculpation under Delaware law."},"claim":"BOSTON SCIENTIFIC CORP: Stockholders approved amendments to the Third Restated Certificate of Incorporation to eliminate supermajority voting provisions, implement clarifying changes, and provide for officer exculpation under Delaware law (effective 2026-05-05).","evidence_excerpt":"approved amendments (the “Charter Amendments”) to the Company’s Third Restated Certificate of Incorporation, as described in the Company’s definitive proxy statement for the Annual Meeting filed on March 18, 2026 (the “Proxy Statement”) to (a) eliminate supermajority voting provisions contained therein, as well as to eliminate certain inoperative provisions and implement other clarifying and correcting changes, and (b) provide for exculpation of certain of our officers in certain circumstances as permitted by Delaware law. The Charter Amendments became effective upon the filing of the Company’s Fourth Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on May 5, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-26-000036","anchor_url":"https://secwatch.observer/filing/0000885725-26-000036#claim-70cc581e8f2faf9858999344c49c7a060148f911","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000036/0000885725-26-000036-index.htm"},{"fact_type":"earnings_release","fact_key":"5d7ed3115df4e861bbf4c70c44845378d0a42584","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-04-22T23:59:59+00:00","payload":{"eps_text":"$0.80","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$1.341 billion or $0.90 per share (EPS)","period_text":"first quarter ended March 31, 2026","report_date":"2026-04-22","result_type":"reported_results","revenue_text":"$5.203 billion"},"claim":"BOSTON SCIENTIFIC CORP reported first quarter ended March 31, 2026 results: revenue $5.203 billion, net income $1.341 billion or $0.90 per share (EPS), EPS $0.80.","evidence_excerpt":"(EX-99.1) ---\n\nBoston Scientific announces results for first quarter 2026 Marlborough, Mass. (April 22, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational 1 and organic 2 basis, all compared to the prior year period. The","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0000885725-26-000031","anchor_url":"https://secwatch.observer/filing/0000885725-26-000031#claim-5d7ed3115df4e861bbf4c70c44845378d0a42584","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/0000885725-26-000031-index.htm"},{"fact_type":"debt_financing","fact_key":"b2b72c8d064bd3714f2906972843af0af86794a1","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-02-26T23:59:59+00:00","payload":{"counterparty":"Wells Fargo Bank, National Association","effective_date":"2026-02-26","event":"incurrence","instrument_type":"term_loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"364-day delayed draw","principal_text":"up to $1.000 billion"},"claim":"BOSTON SCIENTIFIC CORP incurred term loan of up to $1.000 billion with Wells Fargo Bank, National Association maturing 364-day delayed draw.","evidence_excerpt":"by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. Under the Term Loan Credit Agreement, the Company may borrow (i) a 364-day delayed draw term loan in an aggregate principal amount of up to $1.000 billion","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-26-000017","anchor_url":"https://secwatch.observer/filing/0000885725-26-000017#claim-b2b72c8d064bd3714f2906972843af0af86794a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm"},{"fact_type":"debt_financing","fact_key":"6b02d2bb1d4041edb26beea72b50e2b1cd37e5e9","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-02-26T23:59:59+00:00","payload":{"counterparty":"Wells Fargo Bank, National Association","effective_date":"2026-02-26","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"Term SOFR determined for the interest period plus the applicable margin based on","item_codes_triggered":["2.03"],"maturity_text":"the date that is 364 days from the earlier of (i) the date that any loans under the 364-Day Revolving Credit Agreement are available to be drawn on, or (ii) the","principal_text":"$2.000 billion"},"claim":"BOSTON SCIENTIFIC CORP incurred revolving credit of $2.000 billion with Wells Fargo Bank, National Association at Term SOFR determined for the interest period plus the applicable margin based on maturing the date that is 364 days from the earlier of (i) the date that any loans under the 364-Day Revolving Credit Agreement are available to be drawn on, or (ii) the.","evidence_excerpt":"On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-26-000017","anchor_url":"https://secwatch.observer/filing/0000885725-26-000017#claim-6b02d2bb1d4041edb26beea72b50e2b1cd37e5e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm"},{"fact_type":"debt_financing","fact_key":"f23861177ed910752b79ccd99339eb73507b1df9","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-02-26T23:59:59+00:00","payload":{"counterparty":"Wells Fargo Bank, National Association","effective_date":"2026-02-26","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"Term SOFR determined for the interest period plus the applicable margin based on","item_codes_triggered":["2.03"],"maturity_text":"February 26, 2031","principal_text":"$3.000 billion"},"claim":"BOSTON SCIENTIFIC CORP incurred revolving credit of $3.000 billion with Wells Fargo Bank, National Association at Term SOFR determined for the interest period plus the applicable margin based on maturing February 26, 2031.","evidence_excerpt":"On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-26-000017","anchor_url":"https://secwatch.observer/filing/0000885725-26-000017#claim-f23861177ed910752b79ccd99339eb73507b1df9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm"},{"fact_type":"material_agreement","fact_key":"de86295b027db259ccec970b085f612a8d04903d","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Term Loan Credit Agreement","agreement_type":"credit_facility","counterparty":"Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto","effective_date":"2026-02-26","item_codes_triggered":["1.01"],"value_text":"$6.000 billion"},"claim":"BOSTON SCIENTIFIC CORP entered into Term Loan Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $6.000 billion (effective 2026-02-26).","evidence_excerpt":"On February 26, 2026, the Company entered into a $6.000 billion term loan credit agreement (the “ Term Loan Credit Agreement ” and together with the 2026 Revolving Credit Agreement and the 364-Day Revolving Credit Agreement, the “ 2026 Credit Agreements ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-26-000017","anchor_url":"https://secwatch.observer/filing/0000885725-26-000017#claim-de86295b027db259ccec970b085f612a8d04903d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm"},{"fact_type":"material_agreement","fact_key":"21aa53e153eb94742e70c9f054af419686f8d145","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"364-Day Revolving Credit Agreement","agreement_type":"credit_facility","counterparty":"Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto","effective_date":"2026-02-26","item_codes_triggered":["1.01"],"value_text":"$2.000 billion"},"claim":"BOSTON SCIENTIFIC CORP entered into 364-Day Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $2.000 billion (effective 2026-02-26).","evidence_excerpt":"On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-26-000017","anchor_url":"https://secwatch.observer/filing/0000885725-26-000017#claim-21aa53e153eb94742e70c9f054af419686f8d145","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm"},{"fact_type":"material_agreement","fact_key":"cba15c69bc86aed9a8628112bb3638d7b70f3907","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"2026 Revolving Credit Agreement","agreement_type":"credit_facility","counterparty":"Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto","effective_date":"2026-02-26","item_codes_triggered":["1.01"],"value_text":"$3.000 billion"},"claim":"BOSTON SCIENTIFIC CORP entered into 2026 Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $3.000 billion (effective 2026-02-26).","evidence_excerpt":"On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-26-000017","anchor_url":"https://secwatch.observer/filing/0000885725-26-000017#claim-cba15c69bc86aed9a8628112bb3638d7b70f3907","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm"},{"fact_type":"material_agreement","fact_key":"bd302a40bc8402ee1ea97e44e130af8de36083cf","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-01-15T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"Penumbra, Inc.","effective_date":"2026-01-14","item_codes_triggered":["1.01"],"value_text":null},"claim":"BOSTON SCIENTIFIC CORP entered into Agreement and Plan of Merger with Penumbra, Inc. (effective 2026-01-14).","evidence_excerpt":"On January 14, 2026, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Pinehurst Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Penumbra, Inc., a Delaware corporation (“ Penumbra ”), providing for the merger of Merger Sub with and into Penumbra (the “ Merger ”), with Penumbra surviving the Merger as a wholly owned subsidiary of the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000947871-26-000037","anchor_url":"https://secwatch.observer/filing/0000947871-26-000037#claim-bd302a40bc8402ee1ea97e44e130af8de36083cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000094787126000037/0000947871-26-000037-index.htm"},{"fact_type":"executive_change","fact_key":"10c77468ad","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2025-04-23T23:59:59+00:00","payload":{"action":"promoted","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-30","interim":false,"role":"Executive Vice President and Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jonathan Monson was appointed as Executive Vice President and Chief Financial Officer at BOSTON SCIENTIFIC CORP.","evidence_excerpt":"Jonathan Monson, who currently serves as Senior Vice President, Investor Relations, has been promoted to Executive Vice President and Chief Financial Officer of the Company effective as of June 30, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000885725-25-000024","anchor_url":"https://secwatch.observer/filing/0000885725-25-000024#claim-10c77468ad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000024/0000885725-25-000024-index.htm"},{"fact_type":"executive_change","fact_key":"ed9293db2d","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2025-04-23T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-06-29","interim":false,"role":"Executive Vice President and Chief Financial Officer","role_category":"cfo","successor_name":"Jonathan Monson","successor_named":true},"claim":"Daniel J. Brennan departed as Executive Vice President and Chief Financial Officer at BOSTON SCIENTIFIC CORP.","evidence_excerpt":"On April 23, 2025, Boston Scientific Corporation (the “Company”) announced that Daniel J. Brennan has decided to retire from his role as Executive Vice President and Chief Financial Officer of the Company effective as of June 29, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000885725-25-000024","anchor_url":"https://secwatch.observer/filing/0000885725-25-000024#claim-ed9293db2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000024/0000885725-25-000024-index.htm"},{"fact_type":"executive_change","fact_key":"25ad19cf4a","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2025-02-12T23:59:59+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Charles J. Dockendorff departed as Director at BOSTON SCIENTIFIC CORP.","evidence_excerpt":"Charles J. Dockendorff informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000885725-25-000009","anchor_url":"https://secwatch.observer/filing/0000885725-25-000009#claim-25ad19cf4a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000009/0000885725-25-000009-index.htm"},{"fact_type":"executive_change","fact_key":"5cc2a8231e","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-07-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David C. Habiger was appointed as Director at BOSTON SCIENTIFIC CORP.","evidence_excerpt":"appointed David C. Habiger, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective July 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000885725-24-000063","anchor_url":"https://secwatch.observer/filing/0000885725-24-000063#claim-5cc2a8231e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000063/0000885725-24-000063-index.htm"},{"fact_type":"executive_change","fact_key":"82f8fa1ee2","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-05-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Cheryl Pegus was appointed as Director at BOSTON SCIENTIFIC CORP.","evidence_excerpt":"appointed Cheryl Pegus, MD, MPH, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective May 8, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000885725-24-000050","anchor_url":"https://secwatch.observer/filing/0000885725-24-000050#claim-82f8fa1ee2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000050/0000885725-24-000050-index.htm"},{"fact_type":"governance_change","fact_key":"8c12689846f31325950b176c486ea218c8fdf06c","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-05-06T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-05-02","item_codes_triggered":["5.03"],"summary_text":"Amendment and restatement of By-Laws to provide for advance notice and universal proxy rule updates, including expanded disclosures, revised advance notice period, and compliance requirements for Rule 14a-19, effective May 2, 2024."},"claim":"BOSTON SCIENTIFIC CORP: Amendment and restatement of By-Laws to provide for advance notice and universal proxy rule updates, including expanded disclosures, revised advance notice period, and compliance requirements for Rule 14a-19, effective May 2, 2024 (effective 2024-05-02).","evidence_excerpt":"The By-Laws, as so amended and restated, became effective May 2, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-24-000048","anchor_url":"https://secwatch.observer/filing/0000885725-24-000048#claim-8c12689846f31325950b176c486ea218c8fdf06c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000048/0000885725-24-000048-index.htm"},{"fact_type":"earnings_release","fact_key":"03fae87d2bd2f5ce08000bfa5fe33cc863a17cb4","cik":885725,"ticker":"BSX","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-04-24T23:59:59+00:00","payload":{"eps_text":"$0.56 for the period","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$495 million or $0.33 per share","period_text":"the first quarter ended March 31, 2024","report_date":"2024-04-24","result_type":"reported_results","revenue_text":"$3.856 billion"},"claim":"BOSTON SCIENTIFIC CORP reported the first quarter ended March 31, 2024 results: revenue $3.856 billion, net income $495 million or $0.33 per share, EPS $0.56 for the period.","evidence_excerpt":"Document Boston Scientific Announces Results for First Quarter 2024 Marlborough, Mass. (April 24, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational 1 basis and 13.1 percent on an organic 2 basis, all compared to the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000885725-24-000040","anchor_url":"https://secwatch.observer/filing/0000885725-24-000040#claim-03fae87d2bd2f5ce08000bfa5fe33cc863a17cb4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/0000885725-24-000040-index.htm"}]}